Article
The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons.
Antimicrobial agents and chemotherapy - 1 May 2016
Lahser Frederick C, Bystol Karin, Curry Stephanie, McMonagle Patricia, Xia Ellen, Ingravallo Paul, Chase Robert, Liu Rong, Black Todd, Hazuda Daria, Howe Anita Y M, Asante-Appiah Ernest
Abstract excerpt
The selection of resistance-associated variants (RAVs) against single agents administered to patients chronically infected with hepatitis C virus (HCV) necessitates that direct-acting antiviral agents (DAAs) targeting multiple viral proteins be developed to overcome failure resulting from emergence of resistance. The combination of grazoprevir (formerly MK-5172), an NS3/4A protease inhibitor, and elbasvir...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.